DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Phase 2

Completed

Conditions: Hidradenitis Suppurativa (HS)

Interventions: Drug: Upadacitinib
Drug: Placebo

First Posted Date: 2020-06-12

Last Posted Date: 2023-02-06

Lead Sponsor: AbbVie

Target Recruit Count: 68

Registration Number: NCT04430855

Locations: 🇺🇸
Medical Dermatology Specialist /ID# 221084, Phoenix, Arizona, United States
🇺🇸
Beth Israel Deaconess Medical Center /ID# 218306, Boston, Massachusetts, United States
🇯🇵
Takagi Dermatology Clinic /ID# 218587, Obihiro-shi, Hokkaido, Japan

and more 23 locations

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

Phase 1

Terminated

Conditions: Presbyopia

Interventions: Drug: AGN-241622
Drug: Vehicle

First Posted Date: 2020-05-27

Last Posted Date: 2024-02-06

Lead Sponsor: AbbVie

Target Recruit Count: 80

Registration Number: NCT04403763

Locations: 🇺🇸
Kannarr Eye Care /ID# 236718, Pittsburg, Kansas, United States
🇺🇸
North Valley Eye Medical Group, Inc. /ID# 236686, Mission Hills, California, United States
🇺🇸
The Eye Care Institute /ID# 234507, Louisville, Kentucky, United States

and more 7 locations

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

Phase 3

Active, not recruiting

Conditions: Myelodysplastic Syndrome (MDS)

Interventions: Drug: Venetoclax
Drug: Placebo
Drug: Azacitidine

First Posted Date: 2020-05-26

Last Posted Date: 2024-06-20

Lead Sponsor: AbbVie

Target Recruit Count: 531

Registration Number: NCT04401748

Locations: 🇺🇸
Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 223727, Dallas, Texas, United States
🇺🇸
UPMC Hillman Cancer Ctr /ID# 223201, Pittsburgh, Pennsylvania, United States
🇨🇳
China Medical University Hospital /ID# 218987, Taichung, Taiwan

and more 217 locations

Cariprazine Pediatric ASD PK Study

Phase 1

Completed

Conditions: Autism Spectrum Disorder

Interventions: Drug: Cariprazine

First Posted Date: 2020-05-11

Last Posted Date: 2022-04-12

Lead Sponsor: AbbVie

Target Recruit Count: 24

Registration Number: NCT04382885

Locations: 🇺🇸
Atlanta Center for Medical Research /ID# 233576, Atlanta, Georgia, United States
🇺🇸
iResearch Atlanta, LLC /ID# 233614, Decatur, Georgia, United States
🇺🇸
Neuropsychiatric Research Center of Orange County /ID# 233663, Orange, California, United States

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Phase 3

Completed

Conditions: Parkinson's Disease (PD)

Interventions: Drug: Levodopa/Carbidopa (LD/CD)
Drug: ABBV-951
Drug: Placebo for Levodopa/Carbidopa (LD/CD)
Drug: Placebo for ABBV-951

First Posted Date: 2020-05-08

Last Posted Date: 2022-11-18

Lead Sponsor: AbbVie

Target Recruit Count: 174

Registration Number: NCT04380142

Locations: 🇺🇸
University of California, Los Angeles /ID# 216674, Los Angeles, California, United States
🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 216517, Boca Raton, Florida, United States
🇺🇸
Brain Matters Research /ID# 217089, Delray Beach, Florida, United States

and more 73 locations

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Phase 3

Active, not recruiting

Conditions: Parkinson's Disease (PD)

Interventions: Drug: ABBV-951

First Posted Date: 2020-05-07

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 130

Registration Number: NCT04379050

Locations: 🇺🇸
Washington University-School of Medicine /ID# 215472, Saint Louis, Missouri, United States
🇺🇸
Central Texas Neurology Consul /ID# 217013, Round Rock, Texas, United States
🇺🇸
Booth Gardner Parkinson's Care Center /ID# 215535, Kirkland, Washington, United States

and more 48 locations

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

Phase 2

Completed

Conditions: CoronaVirus Induced Disease-2019 (COVID-19)

Interventions: Drug: Placebo
Drug: Ibrutinib

First Posted Date: 2020-05-05

Last Posted Date: 2022-06-01

Lead Sponsor: AbbVie

Target Recruit Count: 46

Registration Number: NCT04375397

Locations: 🇺🇸
Stanford University School of Med /ID# 221954, Stanford, California, United States
🇺🇸
Midway Immunology and Research /ID# 222004, Fort Pierce, Florida, United States
🇺🇸
Triple O Research Institute /ID# 222944, West Palm Beach, Florida, United States

and more 6 locations

A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2020-04-29

Last Posted Date: 2024-02-01

Lead Sponsor: AbbVie

Target Recruit Count: 95

Registration Number: NCT04366973

Locations: 🇫🇷
Association Tremplin 17 - Saintes /ID# 218708, Saintes, Nouvelle-Aquitaine, France
🇫🇷
Centre de soin d'accompagnement et de prevention en addictologie-Paul Guiraud /ID# 218710, Bagneux, Ile-de-France, France
🇫🇷
CEID Bearn addictions /ID# 221279, Pau, France

and more 27 locations

Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2020-04-20

Last Posted Date: 2022-06-09

Lead Sponsor: AbbVie

Target Recruit Count: 99

Registration Number: NCT04352309

Locations: 🇷🇺
Irkutsk Regional Center for the Prevention and Control of AIDS and Infections /ID# 225499, Irkutsk, Russian Federation
🇷🇺
South Ural State Medical University /ID# 225501, Chelyabinsk, Russian Federation
🇷🇺
S. P. Botkin City Hospital /ID# 225500, Oryol, Russian Federation

and more 3 locations

Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets

Recruiting

Conditions: Rheumatoid Arthritis (RA)

First Posted Date: 2020-04-09

Last Posted Date: 2025-03-03

Lead Sponsor: AbbVie

Target Recruit Count: 1000

Registration Number: NCT04340115

Locations: 🇯🇵
Hidaka Clinic /ID# 240660, Ichihara, Chiba, Japan
🇯🇵
Ito Clinic /ID# 248812, Ichikawa-shi, Chiba, Japan
🇯🇵
Nishio Municipal Hospital /ID# 238575, 直方市, Fukuoka, Japan

and more 1001 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy